WO2001025269A3 - Nouveau recepteur couple a la proteine g humaine - Google Patents

Nouveau recepteur couple a la proteine g humaine Download PDF

Info

Publication number
WO2001025269A3
WO2001025269A3 PCT/EP2000/009584 EP0009584W WO0125269A3 WO 2001025269 A3 WO2001025269 A3 WO 2001025269A3 EP 0009584 W EP0009584 W EP 0009584W WO 0125269 A3 WO0125269 A3 WO 0125269A3
Authority
WO
WIPO (PCT)
Prior art keywords
igs4
polynucleotides
polypeptides
disorders
family
Prior art date
Application number
PCT/EP2000/009584
Other languages
English (en)
Other versions
WO2001025269A2 (fr
Inventor
Willy Deleersnijder
Claudia Berger
Christiane Loeken
Guy Nys
Jacob Venema
Original Assignee
Solvay Pharm Bv
Willy Deleersnijder
Claudia Berger
Christiane Loeken
Guy Nys
Jacob Venema
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2001528209A priority Critical patent/JP2003521894A/ja
Priority to AU21536/01A priority patent/AU779993B2/en
Priority to CA002379462A priority patent/CA2379462A1/fr
Priority to US10/088,744 priority patent/US6998255B1/en
Priority to EP00984940A priority patent/EP1218412A2/fr
Priority to IL14788900A priority patent/IL147889A0/xx
Application filed by Solvay Pharm Bv, Willy Deleersnijder, Claudia Berger, Christiane Loeken, Guy Nys, Jacob Venema filed Critical Solvay Pharm Bv
Publication of WO2001025269A2 publication Critical patent/WO2001025269A2/fr
Publication of WO2001025269A3 publication Critical patent/WO2001025269A3/fr
Priority to IL147889A priority patent/IL147889A/en
Priority to US10/770,583 priority patent/US7151165B2/en
Priority to US11/170,166 priority patent/US20050272122A1/en
Priority to US11/170,351 priority patent/US7459292B2/en
Priority to US11/170,153 priority patent/US7459279B2/en
Priority to IL196053A priority patent/IL196053A0/en
Priority to IL206564A priority patent/IL206564A0/en
Priority to IL206566A priority patent/IL206566A0/en
Priority to IL206565A priority patent/IL206565A0/en
Priority to IL206568A priority patent/IL206568A0/en
Priority to IL206567A priority patent/IL206567A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)

Abstract

L'invention concerne des nouveaux polynucléotides identifiés, des polypeptides codés par ces derniers et l'utilisation et la production de ces polynucléotides et polypeptides. Les polynucléotides et les polypeptides de la présente invention sont notamment apparentés à la famille de récepteurs couplée à la protéine G, appelée famille IGS4. L'invention concerne l'inhibition ou l'activation de l'action de ces polynucléotides et polypeptides, un vecteur contenant lesdits polynucléotides, une cellule hôte contenant ce vecteur et des animaux transgéniques dans lesquels le gène ISG4 est surexprimé, mal exprimé, sous-exprimé ou supprimé (animaux knock out). L'invention concerne également un procédé de criblage de composés capables de servir d'agoniste ou d'antagoniste de ladite famille IGS4 de récepteurs couplés à la protéine G, et l'utilisation des polypeptides et des polynucléotides IGS4 et des agonistes et des antagonistes de la famille de récepteurs IGS4 dans le traitement du système nerveux périphérique, des troubles psychiatriques et SNC dont la schizophrénie, des troubles de l'angoisse paroxystique épisodique, tels que le trouble obsessionnel compulsif, des troubles liés au stress post-traumatique, de la phobie et la peur, de troubles de dépression graves, du trouble bipolaire, de la maladie de Parkinson, du trouble de l'angoisse général, de l'autisme, des délires, de la sclérose en plaques, de la maladie d'Alzheimer/démence et d'autres maladies neurodégénératives, des déficiences mentales graves, de la dyskinésie, de la maladie de Huntington, du syndrome de Tourette, des tics, des tremblements, de la dystonie, des spasmes, de l'anorexie, de la boulimie, des attaques cérébrales, de l'addiction/de la dépendance/du manque, des troubles du sommeil, de l'épilepsie, de la migraine, du trouble de l'attention/de l'hyperactivité (TDAH), des maladies cardiovasculaires dont l'insuffisance cardiaque, de l'angine de poitrine, des arythmies, de l'infarctus du myocarde, de l'hypertrophie cardiaque, de l'hypotension, de l'hypertension, p.ex. l'hypertension essentielle, l'hypertension rénale ou l'hypertention pulmonaire, de la thrombose, de l'artériosclérose, des spasmes vasculaires cérébraux, de l'hémorragie sous-arachnoïdien, de l'ischémie cérébrale, de l'infarctus cérébral, de la maladie vasculaire périphérique, de la maladie de Raynaud, des maladies rénales, p. ex. les insuffisances rénales, des dyslipidémies, de l'obésité, des vomissements, des troubles gastrointestinaux dont le syndrome du colon irritable, des maladies intestinales inflammatoires, du reflux gastrooesophagien pathologique, des troubles de la motilité et des conditions de retard de vidange gastrique, telles que la gastroparésie post-opératoire ou diabétique, et du diabète, des ulcères, p. ex. des ulcères gastriques, de la diarrhée, ainsi que d'autres maladies dont l'ostéoporose, les inflammations, les infections, telles que les infections bactériennes, fongiques, protozoaires et virales, et particulièrement les infections causées par le VIH-1 ou le VIH-2, la douleur, les cancers, les blessures causées par la chimiothérapie, l'invasion tumorale, les troubles immunitaires, la rétention urinaire, l'asthme, les allergies, l'arthrite, l'hypertrophie bénigne de la prostate, le choc endotoxique, la sepsie, les complications du diabète sucré, et des troubles gynécologiques entre autres, ainsi que des doses diagnostiques pour ces derniers. Les utilisations préférées de la présente invention concernent les troubles du système nerveux, comprenant le système nerveux central (SNC) et le système nerveux périphérique, les troubles du système gastrointestinal et/ou du système cardiovasculaire et/ou du muscle squelettique et/ou de la thyroïde, et/ou également les maladies pulmonaires, les maladies immunologiques et les troubles du système génito-urinaire. L'invention concerne égale
PCT/EP2000/009584 1999-09-24 2000-09-25 Nouveau recepteur couple a la proteine g humaine WO2001025269A2 (fr)

Priority Applications (17)

Application Number Priority Date Filing Date Title
JP2001528209A JP2003521894A (ja) 1999-09-24 2000-09-25 新規のヒトｇ−タンパク質共役型受容体
AU21536/01A AU779993B2 (en) 1999-09-24 2000-09-25 Novel human G-protein coupled receptor
CA002379462A CA2379462A1 (fr) 1999-09-24 2000-09-25 Nouveau recepteur couple a la proteine g humaine
US10/088,744 US6998255B1 (en) 1999-09-24 2000-09-25 Human G-protein coupled receptor
EP00984940A EP1218412A2 (fr) 1999-09-24 2000-09-25 Nouveau recepteur couple a la proteine g humaine
IL14788900A IL147889A0 (en) 1999-09-24 2000-09-25 Novel human g-protein coupled receptor
IL147889A IL147889A (en) 1999-09-24 2002-01-29 Human g-protein coupled receptor
US10/770,583 US7151165B2 (en) 1999-09-24 2004-02-04 Antibodies immunospecific for a novel human G-protein coupled receptor family
US11/170,153 US7459279B2 (en) 1999-09-24 2005-06-30 Binding assay employing IGS4, a human G-protein coupled neuromedin receptor
US11/170,166 US20050272122A1 (en) 1999-09-24 2005-06-30 Novel human G-protein coupled receptor
US11/170,351 US7459292B2 (en) 1999-09-24 2005-06-30 Polynucleotides and expression system of a novel human G-protein coupled receptor
IL196053A IL196053A0 (en) 1999-09-24 2008-12-18 Novel human g-protein coupled receptor
IL206564A IL206564A0 (en) 1999-09-24 2010-06-23 A nucleotide sequence whice is complimentary to a nucleotide encoding an igs4 polypeptide
IL206566A IL206566A0 (en) 1999-09-24 2010-06-23 Use of an antagonist to the igs4 neuromedin receptor polypeptide for the preparation of a medicament for the treatment of a disease related to the expression or acitivity of the igs4 neuromedin receptor polypeptide
IL206565A IL206565A0 (en) 1999-09-24 2010-06-23 An antibody immunospecific for an igs4 polypeptide
IL206568A IL206568A0 (en) 1999-09-24 2010-06-23 A method of determining whether a substance is a potential ligand of igs4 receptor
IL206567A IL206567A0 (en) 1999-09-24 2010-06-23 Use of an agonist to the igs4 neuromdin receptor polypeptide for the preparation of a medicament for the treatment of a disease related to the expression or activity of the igs4 neuromedin receptor ploypeptide

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
NL1013140 1999-09-24
NL1013140 1999-09-24
EP99203140.1 1999-09-24
EP99203140 1999-09-24
EP00202683 2000-07-28
EP00202683.9 2000-07-28
US22204700P 2000-07-31 2000-07-31
US60/222,047 2000-07-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US22204700P Continuation 1999-09-24 2000-07-31

Related Child Applications (6)

Application Number Title Priority Date Filing Date
US10/088,744 A-371-Of-International US6998255B1 (en) 1999-09-24 2000-09-25 Human G-protein coupled receptor
US10088744 A-371-Of-International 2000-09-25
US10/770,583 Division US7151165B2 (en) 1999-09-24 2004-02-04 Antibodies immunospecific for a novel human G-protein coupled receptor family
US11/170,351 Continuation US7459292B2 (en) 1999-09-24 2005-06-30 Polynucleotides and expression system of a novel human G-protein coupled receptor
US11/170,166 Division US20050272122A1 (en) 1999-09-24 2005-06-30 Novel human G-protein coupled receptor
US11/170,153 Division US7459279B2 (en) 1999-09-24 2005-06-30 Binding assay employing IGS4, a human G-protein coupled neuromedin receptor

Publications (2)

Publication Number Publication Date
WO2001025269A2 WO2001025269A2 (fr) 2001-04-12
WO2001025269A3 true WO2001025269A3 (fr) 2001-10-11

Family

ID=27440014

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/009584 WO2001025269A2 (fr) 1999-09-24 2000-09-25 Nouveau recepteur couple a la proteine g humaine

Country Status (7)

Country Link
EP (2) EP1218412A2 (fr)
JP (1) JP2003521894A (fr)
CN (1) CN1249087C (fr)
AU (1) AU779993B2 (fr)
CA (1) CA2379462A1 (fr)
IL (8) IL147889A0 (fr)
WO (1) WO2001025269A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461836B1 (en) 1999-11-05 2002-10-08 Smithkline Beecham Corporation Molecular cloning of a 7TM receptor (AxOR34) and screening methods thereof
US7029857B1 (en) 1999-12-17 2006-04-18 H. Lundbeck A/S Processes for obtaining compounds employing SNORF72 receptors
WO2001081418A1 (fr) 2000-04-27 2001-11-01 Merck & Co., Inc. Nouveau recepteur de la neuromedine u, dit nmur2, et nucleotides codant pour lui
GB0100782D0 (en) * 2001-01-11 2001-02-21 Glaxo Group Ltd Assay
EP1365246A1 (fr) 2002-05-23 2003-11-26 Bayer Ag Diagnostic et traitement des maladies associés au récepteur U2 du neuromedin
WO2004067725A2 (fr) * 2003-01-30 2004-08-12 Regeneron Pharmaceuticals, Inc. Procedes d'identification de modulateurs d'activite mediee par nmur2

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001330A1 (fr) * 1988-08-11 1990-02-22 Terence Bennett UTILISATION DE NEUROMEDINES U8 et U25 COMME COMPOSES THERAPEUTIQUES
US5482835A (en) * 1990-09-13 1996-01-09 Duke University Methods of testing in yeast cells for agonists and antagonists of mammal G-protein coupled receptors
JPH08143597A (ja) * 1994-11-24 1996-06-04 Takeda Chem Ind Ltd ヒト・ニューロテンシンレセプター蛋白質、その製造法および用途
WO1999055732A1 (fr) * 1998-04-24 1999-11-04 Astrazeneca Ab Nouveau recepteur couple a la proteine g
WO2000022131A2 (fr) * 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Recepteurs non-endogenes de la proteine g humaine ayant une activite constitutive

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
AU770871B2 (en) * 1998-10-12 2004-03-04 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human G protein-coupled receptors
JP2003525018A (ja) * 1998-10-13 2003-08-26 アリーナ・フアーマシユーチカルズ・インコーポレーテツド 非内在性の構成的に活性化されるヒトｇタンパク質共役型受容体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001330A1 (fr) * 1988-08-11 1990-02-22 Terence Bennett UTILISATION DE NEUROMEDINES U8 et U25 COMME COMPOSES THERAPEUTIQUES
US5482835A (en) * 1990-09-13 1996-01-09 Duke University Methods of testing in yeast cells for agonists and antagonists of mammal G-protein coupled receptors
JPH08143597A (ja) * 1994-11-24 1996-06-04 Takeda Chem Ind Ltd ヒト・ニューロテンシンレセプター蛋白質、その製造法および用途
WO1999055732A1 (fr) * 1998-04-24 1999-11-04 Astrazeneca Ab Nouveau recepteur couple a la proteine g
WO2000022131A2 (fr) * 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Recepteurs non-endogenes de la proteine g humaine ayant une activite constitutive

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 17 February 1996 (1996-02-17), HINXTON, GB, XP002131652 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 3 July 1995 (1995-07-03), HINXTON, GB, XP002131654 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 4 August 1999 (1999-08-04), HINXTON, GB, XP002131651 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 9 June 1996 (1996-06-09), HINXTON, GB, XP002131653 *
DATABASE WPI Section Ch Week 199632, Derwent World Patents Index; Class B04, AN 1996-318958, XP002131656 *
FUJII RYO ET AL: "Identification of neuromedin U as the cognate ligand of the orphan G protein-coupled receptor FM-3.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 28, 14 July 2000 (2000-07-14), pages 21068 - 21074, XP002163226, ISSN: 0021-9258 *
HOSOYA MASAKI ET AL: "Identification and functional characterization of a novel subtype of neuromedin U receptor.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 38, 22 September 2000 (2000-09-22), pages 29528 - 29532, XP002163224, ISSN: 0021-9258 *
HOWARD ANDREW D ET AL: "Identification of receptors for neuromedin U and its role in feeding.", NATURE (LONDON), vol. 406, no. 6791, 2000, pages 70 - 74, XP000926239, ISSN: 0028-0836 *
MCKEE K.K. ET AL.,: "Cloning and characterization of two human G protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin receptors", GENOMICS, vol. 46(3), 1997, pages 426-434, XP000889897 *
RADDATZ RITA ET AL: "Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 42, 20 October 2000 (2000-10-20), pages 32452 - 32459, XP002163227, ISSN: 0021-9258 *
SHAN LIXIN ET AL: "Identification of a novel neuromedin U receptor subtype expressed in the central nervous system.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 50, 15 December 2000 (2000-12-15), pages 39482 - 39486, XP002163228, ISSN: 0021-9258 *
SZEKERES PHILIP G ET AL: "Neuromedin U is a potent agonist at the orphan G protein-coupled receptor FM3.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 27, 7 July 2000 (2000-07-07), pages 20247 - 20250, XP002163225, ISSN: 0021-9258 *
TAN C.P. ET AL.,: "Cloning and characterization of a human and murine T-cell orphan G-protein-coupled receptor similar to the growth hormone secretagogue and neurotensin receptors", GENOMICS, vol. 52(2), 1998, pages 223-229, XP000879493 *
VITA N ET AL.,: "Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 360, no. 2/3, 6 November 1998 (1998-11-06), pages 265 - 272, XP000879367 *
VITA N ET AL: "CLONING AND EXPRESSION OF A COMPLEMENTARY DNA ENCODING A HIGH AFFINITY HUMAN NEUROTENSIN RECEPTOR", FEBS LETTERS,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 317, no. 1/02, 1 February 1993 (1993-02-01), pages 139-142, XP002048144, ISSN: 0014-5793 *

Also Published As

Publication number Publication date
WO2001025269A2 (fr) 2001-04-12
EP2298803A2 (fr) 2011-03-23
IL206564A0 (en) 2011-07-31
CA2379462A1 (fr) 2001-04-12
CN1249087C (zh) 2006-04-05
EP2298803A3 (fr) 2011-06-22
IL206565A0 (en) 2011-07-31
EP1218412A2 (fr) 2002-07-03
IL206568A0 (en) 2011-07-31
IL206567A0 (en) 2011-07-31
JP2003521894A (ja) 2003-07-22
IL147889A (en) 2010-11-30
IL147889A0 (en) 2002-08-14
CN1399644A (zh) 2003-02-26
IL206566A0 (en) 2011-07-31
AU2153601A (en) 2001-05-10
IL196053A0 (en) 2011-08-01
AU779993B2 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
Guerrini et al. A new selective antagonist of the nociceptin receptor
Lundell et al. Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY
Oliveira et al. The angiotensin II AT1 receptor structure-activity correlations in the light of rhodopsin structure
WO2000022131A3 (fr) Recepteurs non-endogenes de la proteine g humaine ayant une activite constitutive
WO2005037071A3 (fr) Analyse de la voie de signalisation de la tyrosine kinase de recepteur pour diagnostic et therapie
WO2001042288A3 (fr) Recepteurs couples a la proteine g
WO2001025269A3 (fr) Nouveau recepteur couple a la proteine g humaine
WO2002084286A1 (fr) Procede de criblage
WO2005031309A3 (fr) Analyses de complementation de fragments proteiques pour recepteurs couples a la proteine g et leurs voies de signalisation
WO2000023588A3 (fr) Recepteurs couples a la proteine g
WO2001087937A3 (fr) Recepteurs couples aux proteines g
WO2000000611A3 (fr) Recepteur 14273, recepteur couple a une proteine g
WO2001098323A3 (fr) Recepteurs couples a la proteine g
AU2001296033A1 (en) Novel guanosine triphosphate (gtp) binding protein-coupled receptor protein, bg37
WO2003018798A3 (fr) Recepteur couple aux proteines g nouvellement identifie et sequences d'adn de ce recepteur
WO2002102839A3 (fr) Nouveaux recepteurs couples a une proteine g et sequences d'adn de ceux-ci
WO2000050563A3 (fr) Recepteur couple a une proteine g ressemblant aux recepteurs de galanine
Petitet et al. Further demonstration that [Pro9]‐substance P is a potent and selective ligand of NK‐1 tachykinin receptors
WO2000020590A3 (fr) Proteines de recepteurs couples a des proteines g
EP0845529A3 (fr) Récepteur humain couplé à la protéine G, cloné à partir d'une banque d'ADN complémentaire de cerveau foetal
EP0908452A3 (fr) Procédé pour la préparation des indazoles-3-substitués
WO2001072836A3 (fr) Recepteurs couples a une proteine g
Corbett et al. Opioid receptors
WO2002026825A3 (fr) Récepteurs couplés à la protéine g
WO2003073107A3 (fr) Recepteur de neuropeptides et ses applications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000984940

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 147889

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2379462

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 008122652

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 21536/01

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 528209

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10088744

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000984940

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 21536/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 196053

Country of ref document: IL